Renalytix Share Discussion Threads

[wan] 29/9/2019 06:24

Renalytix is on 4 shortlists -

Best AIM companies of 2019 named here
by Andrew Hore from interactive investor | 27th September 2019

With the 2019 AIM awards fast approaching, our award-winning AIM writer guesses the winners.



This year, the awards will be held in London on 10th October

[volsung] 17/9/2019 15:07

There's life!!!

[wan] 06/8/2019 08:23

It's worth following the links of the new additions to the Advisory Board!

I duly note the update at the end of the RNS -

The Company intends to be in a position to announce the appointment of a new Non-Executive Director and healthcare industry veteran in advance of the Company's AGM at the end of September 2019.

[wan] 29/7/2019 07:20

I note today's RNS Non-Regulatory, that a very key/influential individual has been recruited.

[wan] 24/7/2019 06:59

My interpretation of the need and use of Placing, which was "significantly oversubscribed with strong demand received from existing and new shareholders", was to accelerate matters, this has now been confirmed in last nights announcement -

James McCullough, CEO of RenalytixAI, commented:

"We are pleased to have achieved an oversubscribed placing supported by a broad range of investors, and thank them for their support. The Company will now be better resourced to support the acceleration of its commercial plans, having made rapid progress against its objectives as set out at the time of its IPO in November 2018."

[volsung] 23/7/2019 08:20

Ah ye olde placing hath arrived. Oh well will give the co funds to progress.

[tidy 2] 12/7/2019 11:46

IQA 7m cap due FDA approval for their AI stonechecker tech also. Massive news from the Whitehouse.

[wan] 12/7/2019 07:19

Today's news implies that the above really is a 'very relevant' read!

[wan] 11/7/2019 12:10

Renalytix just tweeted highlighting the following, which is a worthy read -

EXECUTIVE ORDERS

Executive Order on Advancing American Kidney Health
HEALTHCARE

[wan] 11/7/2019 06:41

Renalytix - The right products at the right time!

10th July

Trump signs executive order revamping kidney disease care, includes better access to home dialysis, transplants

Careful treatment — including control of diabetes and high blood pressure, the two main culprits — can help prevent further kidney deterioration. But more than 700,000 people have end-stage renal disease, meaning their kidneys have failed, and require either a transplant or dialysis to survive. Only about a third received specialized kidney care before they got so sick.

Among the initiatives that take effect first:

—Medicare payment changes that would provide a financial incentive for doctors and clinics to help kidney patients stave off end-stage disease by about six months.

—A bonus to kidney specialists who help prepare patients for early transplant, with steps that can begin even before they need dialysis.

Full story -

[fardistanthills] 10/7/2019 20:59

sorry about that - very bad taste - the dung bit - not that I have - tasted it that is

[volsung] 10/7/2019 16:09

What a difference a letter makes :)

[wan] 10/7/2019 14:24

9degrees...I actually wish I could ;-)

[9degrees] 10/7/2019 14:02

wan thought you had overslept

[wan] 10/7/2019 05:46

I had a very busy day yesterday and missed the 9:30 am announcement of Positive Interim Results for KidneyIntelX(TM) in Expanded Validation Study.

'KidneyIntelX continues to demonstrate significant performance improvements over current diagnostic standards and now in a multi-centre environment.'

Renalytix has not put a foot wrong in the development plan process, they continue to work closely with the FDA under Breakthrough Device designation and thus we remain on schedule for the commercial launch of KidneyIntelX(TM) in the second half of this year. And a very large market awaits Renalytix products -

7th July 2019
Trump aims to shake up kidney care market

The health department also will announce an agency-wide initiative to encourage home dialysis and ramp up better prevention and screening for kidney disease.

The closely guarded plan has the potential to upend how kidney care is delivered. U.S. dialysis centers reported about $24 billion in revenue last year, mostly at clinics owned by DaVita and Fresenius. Medicare also spends more than $114 billion on kidney care per year, according to the most recent government figures— $79 billion to cover people with chronic kidney disease and another $35 billion on end-stage renal disease.

Full story -

[wan] 08/7/2019 08:01

I had not spotted the RNS non-regulatory announcement which should be read in conjunction with the above. Very positive progress continues!

[wan] 08/7/2019 07:56

Renalytix tweet highlights the following article -

A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection

Journal of the American Society of Nephrology
Vol. 30, Issue 7
July 2019

Abstract
Background In kidney transplant recipients, surveillance biopsies can reveal, despite stable graft function, histologic features of acute rejection and borderline changes that are associated with undesirable graft outcomes. Noninvasive biomarkers of subclinical acute rejection are needed to avoid the risks and costs associated with repeated biopsies.

Methods We examined subclinical histologic and functional changes in kidney transplant recipients from the prospective Genomics of Chronic Allograft Rejection (GoCAR) study who underwent surveillance biopsies over 2 years, identifying those with subclinical or borderline acute cellular rejection (ACR) at 3 months (ACR-3) post-transplant. We performed RNA sequencing on whole blood collected from 88 individuals at the time of 3-month surveillance biopsy to identify transcripts associated with ACR-3, developed a novel sequencing-based targeted expression assay, and validated this gene signature in an independent cohort.

Results Study participants with ACR-3 had significantly higher risk than those without ACR-3 of subsequent clinical acute rejection at 12 and 24 months, faster decline in graft function, and decreased graft survival in adjusted Cox analysis. We identified a 17-gene signature in peripheral blood that accurately diagnosed ACR-3, and validated it using microarray expression profiles of blood samples from 65 transplant recipients in the GoCAR cohort and three public microarray datasets. In an independent cohort of 110 transplant recipients, tests of the targeted expression assay on the basis of the 17-gene set showed that it identified individuals at higher risk of ongoing acute rejection and future graft loss.

Conclusions Our targeted expression assay enabled noninvasive diagnosis of subclinical acute rejection and inflammation in the graft and may represent a useful tool to risk-stratify kidney transplant recipients.

Full article access requires subscription or purchase -

[wan] 01/7/2019 07:45

The momentum behind the progress that Renalytix is making continues ;-)

[wan] 26/6/2019 08:17

An interesting article from one of the Renalytix founders -

Can Artificial Intelligence Solve The Chronic Kidney Disease Epidemic?

by Girish Nadkarni, MD, Assistant Professor in the Department of Medicine, Division of Nephrology, at Mount Sinai, and Co-Founder of RenalytixAI

25th June 2019

Current Challenges in Diagnosing and Treating Kidney Disease

Kidney disease is one of the most expensive medical conditions in the United States, estimated to cost the U.S. healthcare system $114 billion a year. Much of this cost stems from the inability of providers to easily diagnose patients and determine the right course of treatment for patients with early-stage disease, using currently available tools. This is one of several key challenges facing the industry today, and one where AI is poised to make a big impact.

There is also hope that this combination of AI, EHR data and biomarkers will be able to help define specific types of kidney disease, and determine which pharmaceuticals that are currently utilized for other indications can be repurposed for CKD.

We’re just beginning to see the potential AI holds for healthcare and particularly CKD, one of the world’s fast-growing epidemics, and the excitement continues to grow in the nephrology community.

Full story -

The facts in terms of prevalence and cost in the US -

UNITED STATES RENAL DATA SYSTEM

New Report Captures the High Burden, High Cost and Low Awareness of Kidney Disease in the United States

The United States Renal Data System’s Annual Data Report highlights key data and trends for kidney disease in 2018

Ann Arbor, Mich. — The United States Renal (Kidney) Data System (USRDS) has just released its Annual Data Report (ADR) for 2018 on the state of kidney disease for the country. The report is prepared by the USRDS Coordinating Center based at the University of Michigan’s Kidney Epidemiology and Cost Center in partnership with Arbor Research Collaborative for Health.

The USRDS remains the most comprehensive resource for those seeking detailed information, data and trends on a wide variety of kidney disease topics. The report is entirely web based (www.usrds.org), and is also regularly published in the American Journal of Kidney Diseases.

Other important highlights from the ADR include:

* The death rates among patients on dialysis are no longer decreasing. This development deserves greater attention by practitioners, policy makers and researchers.
* The vast majority (i.e. 80 percent) of new patients on dialysis continue to initiate dialysis with a catheter, a practice that has changed little over time, and one where concerted efforts to improve care are necessary to help improve patient outcomes.
* Use of home dialysis therapies (i.e. peritoneal dialysis and home hemodialysis) remains substantially lower in the U.S. than in many other countries.
Kidney disease is expensive. The total Medicare spending on both CKD and ESRD patients was in excess of $114 billion. Accompanying chronic diseases such as diabetes and heart failure compound the cost of caring for these individuals, and kidney disease has been deemed a “cost multiplier” for this reason. Substantial cost savings may result if these conditions are detected and treated early, therefore preventing further complications.
* There is encouraging news on kidney disease among diabetics. The prevalence of kidney disease among individuals with diabetes decreased from 44 percent to 36 percent over the last two decades. However, the same trend has not been observed among individuals with kidney disease and hypertension.
* Acute kidney injury (AKI) is a major risk factor for chronic kidney disease, ESRD, mortality, and higher costs among older Medicare recipients. Hospitalizations for AKI among individuals of all ages is associated with an increased chance of being diagnosed with CKD in the year following hospital discharge.

Full details -

[andrewbaker] 24/6/2019 14:33

Bought more on 14 June, and more today: the science and market for this combined means it's simply undervalued, not just in price, given the potential turnover and profit in a short time forward, but also in the good it'll do in the kidney disease area: just taking people off of dialysis or the need for it will save billions, plus time and discomfort aplenty. Just watch this motor ... :)

[volsung] 24/6/2019 11:11

managed to get a few more of these at 299p

[ahmedbin69] 24/6/2019 08:29

Guys buy IQAI will do the same as renx did

[andrewbaker] 17/6/2019 08:47

I bought more last week, and will keep buying: this share is going places; just look into the business, and you'll find one growing company with good product in a medical area that will always be in demand. There could even be a takeover bid from a bigger outfit in the offing.